newsfilter
← Earnings
Earnings Releases·

PTC Therapeutics — Third Quarter 2026 Earnings Summary

PTC Therapeutics reported third-quarter 2026 total revenue of $358 million, driven by $276 million in product revenue. Sephience generated $182 million in revenue during the quarter, bringing the total active patient count to over 2,000 worldwide. The company raised its full-year 2026 total revenue guidance to a range of $1.29 billion to $1.32 billion and product revenue guidance to $960 million to $990 million. Additionally, PTC acquired the ST-920 Fabry disease gene therapy for $111 million upfront, with a Biologics License Application submission expected in the fourth quarter of 2026.

Company
PTC THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology